Holen Sie sich die Stockscreener-App
10.50
0.66%
-0.07
Schlusskurs vom Vortag:
$10.57
Offen:
$10.67
24-Stunden-Volumen:
96,202
Relative Volume:
1.04
Marktkapitalisierung:
$336.79M
Einnahmen:
$26.00M
Nettoeinkommen (Verlust:
$-219.71M
KGV:
-0.2108
EPS:
-49.8
Netto-Cashflow:
$-51.37M
1W Leistung:
+1.35%
1M Leistung:
-27.29%
6M Leistung:
-51.61%
1J Leistung:
-43.24%
1-Tages-Spanne:
$10.19
$10.67
1-Wochen-Bereich:
$10.19
$13.07
52-Wochen-Spanne:
$8.85
$41.87
Cartesian Therapeutics Inc Stock (RNAC) Company Profile
Firmenname
Cartesian Therapeutics Inc
Sektor
Branche
Telefon
301-348-8698
Adresse
7495 NEW HORIZON WAY, FREDERICK
Vergleichen Sie RNAC mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RNAC
Cartesian Therapeutics Inc
|
10.50 | 336.79M | 26.00M | -219.71M | -51.37M | -49.80 |
|
VRTX
Vertex Pharmaceuticals Inc
|
489.10 | 127.47B | 11.02B | -535.60M | -978.00M | -2.20 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.16 | 62.43B | 14.20B | 4.41B | 3.54B | 38.28 |
|
ARGX
Argen X Se Adr
|
596.20 | 37.03B | 2.19B | 833.04M | -1.28B | 12.71 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
234.56 | 31.06B | 2.25B | -278.16M | -42.59M | -2.17 |
|
ONC
Beigene Ltd Adr
|
230.98 | 26.16B | 3.81B | -644.79M | -669.77M | -6.24 |
Cartesian Therapeutics Inc Stock (RNAC) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2024-12-19 | Eingeleitet | BTIG Research | Buy |
| 2024-08-06 | Eingeleitet | TD Cowen | Buy |
| 2024-07-02 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2024-06-04 | Eingeleitet | Oppenheimer | Outperform |
| 2024-05-24 | Eingeleitet | Mizuho | Buy |
| 2024-04-23 | Bestätigt | H.C. Wainwright | Buy |
| 2024-04-23 | Eingeleitet | Leerink Partners | Outperform |
| 2023-08-18 | Herabstufung | SVB Securities | Outperform → Market Perform |
| 2022-06-14 | Bestätigt | Needham | Buy |
| 2022-06-06 | Eingeleitet | SVB Leerink | Outperform |
| 2021-06-15 | Eingeleitet | BTIG Research | Buy |
| 2021-01-26 | Hochstufung | Mizuho | Neutral → Buy |
| 2020-10-01 | Herabstufung | Mizuho | Buy → Neutral |
| 2020-10-01 | Herabstufung | William Blair | Outperform → Mkt Perform |
| 2020-06-12 | Herabstufung | Stifel | Buy → Hold |
| 2020-04-28 | Eingeleitet | H.C. Wainwright | Buy |
| 2020-01-29 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2020-01-21 | Eingeleitet | William Blair | Outperform |
| 2018-06-27 | Eingeleitet | Janney | Buy |
| 2017-03-30 | Bestätigt | UBS | Buy |
Alle ansehen
Cartesian Therapeutics Inc Aktie (RNAC) Neueste Nachrichten
Cartesian Therapeutics (RNAC) Stock Gains Momentum In After-Hour Trading - Stocks Telegraph
Corebridge Financial Inc. Increases Holdings in Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics’ (RNAC) Buy Rating Reiterated at Needham & Company LLC - Defense World
Cartesian Therapeutics’ (RNAC) Buy Rating Reiterated at HC Wainwright - Defense World
Cartesian Therapeutics director Timothy Springer buys $1.5 million in stock - Investing.com Australia
Cartesian Therapeutics director Timothy Springer buys $1.5 million in stock By Investing.com - Investing.com South Africa
Cell therapy scores year-long benefit in myasthenia gravis, heads to Phase III - The Pharma Letter
US Stocks Futures Trade Mixed Ahead Of Opening Bell: 'Preserve Capital In Conditions Of High Uncertainty,' Says Expert - Benzinga
Cartesian math works out nicely in phase IIb MG trial - BioWorld MedTech
Cartesian Maps Out CAR-T Strategy With Simpler Logistics In Mind - insights.citeline.com
Cartesian Therapeutics Reports Strong 12-Month Data For Lead Cell Therapy In Myasthenia Gravis Patients - Benzinga
Cartesian Therapeutics Unveils Promising Phase 2b Trial Results - TipRanks
Cartesian Therapeutics’ Descartes-08 Observed to Provide Deep and Sustained Benefits Through Month 12 After a Single Course of Therapy in Phase 2b Myasthenia Gravis Trial - GlobeNewswire
Breakthrough: New CAR-T Therapy Maintains 83% Response Rate After 12 Months in Myasthenia Gravis Patients - Stock Titan
Brokerages Set Cartesian Therapeutics, Inc. (NASDAQ:RNAC) PT at $42.14 - Defense World
Cartesian Therapeutics Announces New Employment Inducement Grants - GlobeNewswire
Cartesian Therapeutics Expands Cell Therapy Team with Strategic New Hires - Stock Titan
Cartesian Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare Conference - GlobeNewswire
Leading mRNA Cell Therapy Company Cartesian Takes Center Stage at Needham Healthcare Conference - Stock Titan
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Purchased by Charles Schwab Investment Management Inc. - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Holdings Raised by Bank of New York Mellon Corp - Defense World
Timothy Springer Spends US$1.4m On Cartesian Therapeutics Stock - Yahoo
Cartesian therapeutics director Timothy Springer buys over $1.37 million in stock - Investing.com India
Cartesian therapeutics director Timothy Springer buys over $1.37 million in stock By Investing.com - Investing.com South Africa
Analysts Issue Forecasts for RNAC FY2025 Earnings - Defense World
Cartesian Therapeutics, Inc.'s (NASDAQ:RNAC) Popularity With Investors Under Threat As Stock Sinks 27% - simplywall.st
Cantor Fitzgerald maintains Overweight on Cartesian Therapeutics By Investing.com - Investing.com Canada
Cartesian Therapeutics stock target cut to $40 by H.C. Wainwright - Investing.com Canada
HC Wainwright Has Lowered Expectations for Cartesian Therapeutics (NASDAQ:RNAC) Stock Price - Defense World
Cartesian Therapeutics' Market Cap Drops To US$430m Leaving Insiders With Losses - simplywall.st
Needham & Company LLC Reaffirms Buy Rating for Cartesian Therapeutics (NASDAQ:RNAC) - Defense World
Amgen data ‘muddies’ outlook for Cartesian, says Oppenheimer - Yahoo Finance
Cartesian Therapeutics Full Year 2024 Earnings: EPS Beats Expectations, Revenues Lag - Yahoo Finance
Cartesian Therapeutics Faces Financial Risk from Goodwill and Intangible Asset Impairments Post-Merger - TipRanks
Cartesian Therapeutics Advances mRNA Therapy Pipeline - TipRanks
Cartesian Therapeutics Inc. (RNAC) reports earnings - Quartz
Cartesian Therapeutics reports FY24 EPS ($4.49) vs. ($49.76) last year - TipRanks
Cartesian Therapeutics Reports Full Year 2024 Financial Results and Provides Business Update - The Manila Times
Cartesian Therapeutics, Inc. SEC 10-K Report - TradingView
Cartesian's $214M War Chest Powers Breakthrough Myasthenia Gravis Treatment into Phase 3 - StockTitan
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Shares Bought by Rhumbline Advisers - Defense World
Cartesian Therapeutics, Inc. (NASDAQ:RNAC) Receives $42.86 Average Target Price from Analysts - Defense World
New York State Common Retirement Fund Sells 1,200 Shares of Cartesian Therapeutics, Inc. (NASDAQ:RNAC) - Defense World
Cartesian Therapeutics Announces New Employment Inducement Grant - The Manila Times
Inside Cartesian's Latest Executive Compensation Package: Key Details Revealed - StockTitan
Cartesian Therapeutics Advances Descartes-08 in Clinical Trials - TipRanks
Cartesian Therapeutics (RNAC) Projected to Post Earnings on Thursday - Defense World
Cartesian Therapeutics to Participate in Multiple Upcoming Investor Conferences in February and March 2025 - Nasdaq
Cartesian Therapeutics to Participate in Upcoming Investor Conferences - The Manila Times
Finanzdaten der Cartesian Therapeutics Inc-Aktie (RNAC)
Umsatz
Nettogewinn
Free Cashflow
ENV
Cartesian Therapeutics Inc-Aktie (RNAC) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| SPRINGER TIMOTHY A | Director |
Apr 10 '25 |
Buy |
10.47 |
48,595 |
508,751 |
620,175 |
| SPRINGER TIMOTHY A | Director |
Apr 09 '25 |
Buy |
9.43 |
41,782 |
393,947 |
571,580 |
| SPRINGER TIMOTHY A | Director |
Apr 11 '25 |
Buy |
10.77 |
36,338 |
391,455 |
656,513 |
| SPRINGER TIMOTHY A | Director |
Apr 10 '25 |
Buy |
10.47 |
8,575 |
89,773 |
8,637,273 |
| SPRINGER TIMOTHY A | Director |
Apr 09 '25 |
Buy |
9.43 |
7,373 |
69,517 |
8,628,698 |
| SPRINGER TIMOTHY A | Director |
Apr 11 '25 |
Buy |
10.77 |
6,412 |
69,074 |
8,643,685 |
| SPRINGER TIMOTHY A | Director |
Mar 20 '25 |
Buy |
15.59 |
54,889 |
855,593 |
8,621,325 |
| SPRINGER TIMOTHY A | Director |
Mar 19 '25 |
Buy |
14.97 |
20,234 |
302,962 |
8,566,436 |
| SPRINGER TIMOTHY A | Director |
Mar 18 '25 |
Buy |
14.42 |
14,740 |
212,599 |
8,546,202 |
| SPRINGER TIMOTHY A | Director |
Jan 13 '25 |
Buy |
17.35 |
16,945 |
293,958 |
8,527,440 |
2.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):